



IFW

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Nancy Malsich  
Nancy Malsich

10/20/04  
Date

Applicant: Gilula, et al.	) Group: 1632
	)
Serial No.: 10/788,992	) Confirmation No.: 8173
	)
Filed: February 26, 2004	) Examiner: Unassigned
	)
For: FATTY-ACID AMIDE HYDROLASE	) Our Ref.: TSRI 485.2 Div 2
	)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the applications 08/743,168 and 09/894,790. Application 08/743,168 was filed on November 4, 1996 and has issued as U.S. Patent No. 6,271,015, to which the present application is related by division. Application 09/894,790 was filed on June 28, 2001 and has issued as U.S. Patent No. 6,699,682, to which the present application is related by division. Also, pursuant to 37 CFR §1.98(d), copies of the above

references are not submitted herewith, as they are available in the related patent application 09/980,869.


Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.


Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

Oct 20, 2004  
Date

  
\_\_\_\_\_  
Donald G. Lewis, Reg. No. 28,636

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(858) 784-2937

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
TSRI 485.2SERIAL NO.  
08/743,168APPLICANT  
Gilula, et al.FILING DATE  
11/4/1996GROUP  
1651INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
1		4,165,258	8/21/ 1979	Pye, et al.			

## FOREIGN PATENT DOCUMENTS

M. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)


2	Matsuzaki, et al., "Paradoxical Phase of Sleep: Its Artificial Induction in the Cat by Sodium Butyrate", <u>Science 146:</u> 1328-1329 (1964)
3	Pappenheimer, et al., "Sleep-Promoting Effects of Cerebrospinal Fluid From Sleep-Deprived Goats", <u>Proc. Natl. Acad. Sci. USA 58:</u> 513-517 (1967)
4	Yanagisawa, et al., "A Bromine Compound Isolated from Human Cerebrospinal Fluid", <u>Biochim. Biophys. Acta.</u> 329: 283-294 (1973)
5	Sallanon, et al., "Restoration of Paradoxical Sleep by Cerebrospinal Fluid Transfer to PCPA Pretreated Insomniac Cats", <u>Brain Res. 251:</u> 137-147 (1982)
6	Dewasmes, et al., "Sleep Changes in Long-Term Fasting Geese in Relation to Lipid and Protein Metabolism", <u>Amer. J. Physiol. 247:</u> R663-R671 (1984)
7	Prospéro-Garcia, et al., "Vasoactive Intestinal Polypeptide (VIP) and cerebrospinal fluid (CSF) of Sleep-Deprived Cats Restores REM Sleep in Insomniac Recipients", <u>Brain Res. 385:</u> 169-173 (1986)
8	Abeles, et al., "Enzyme Inhibitors: Ground-State/Transition-State Analogs", <u>Drug Development Research 10:</u> 221-234 (1987)
9	Fagioli, et al., "Decrease of Slow-Wave Sleep in Children with Prolonged Absence of Essential Lipids Intake", <u>Sleep 12:</u> 495-499 (1989)
10	Arafat, et al., "Identification of Fatty Acid Amides in Human Plasma", <u>Life Sciences 45:</u> 1679-1687 (1989)
11	Wakamatsu, et al., "Isolation of Fatty Acid Amide as an Angiogenic Principle from Bovine Mesentery", <u>Biochem. Biophys. Res. Commun. 168:</u> 423-429 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE



ATTY DOCKET NO.  
TSRI 485.2

SERIAL NO.  
08/743,168

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT  
Gilula, et al.

FILING DATE  
11/4/1996

GROUP  
1651

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES      NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

12	Ohkawa, et al., "Microbial Degradation of Fatty Acid Diethanolamide", <u>J. Antibact. Antifung. Agents</u> 18: 371-374 (1990)
13	Mayaux, et al., "Purification, Cloning, and Primary Structure of an Enantiomer-Selective Amidase from <i>Brevibacterium</i> sp. Strain R312: Structural Evidence for Genetic Coupling with Nitrile Hydratase", <u>J. Bacteriology</u> 172: 6764-6773 (1990)
14	Jain, et al., "Fatty Acid Amides: Screening Mode-Based Discovery of Tight-Binding Competitive Inhibitors of Secreted Phospholipases A <sub>2</sub> ", <u>J. Med. Chem.</u> 35: 3584-3586 (1992)
15	Deutsch, et al., "Enzymatic Synthesis and Degradation of Anandamide, A Cannabinoid Receptor Agonist", <u>Biochem. Pharmacol.</u> 46: 791-796 (1993)
16	Childers, et al., "Effects of Anandamide on Cannabinoid Receptors in Rat Brain Membranes", <u>Biochem. Pharmacol.</u> 47: 711-715 (1994)
17	Koutek, et al., "Inhibitors of Arachidonoyl Ethanolamide Hydrolysis", <u>J. Biol. Chem.</u> 269: 22937-22940 (1994)
18	Cravatt, et al., "Chemical Characterization of a Family of Brain Lipids that Induce Sleep", <u>Science</u> 268: 1506-1509 (1995)
19	Ueda, et al., "Partial Purification and Characterization of the Porcine Brain Enzyme Hydrolyzing and Synthesizing Anandamide", <u>J. Biol. Chem.</u> 270: 23823-23827 (1995)
20	Maurelli, et al., "Two Novel Classes of Neuroactive Fatty Acid Amides are Substrates for Mouse Neuroblastoma 'Anandamide Amidohydrolase'", <u>FEBS Letters</u> 377: 82-86 (1995)
21	Patterson, et al., "Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid <i>cis</i> -9-Octadecenamide", <u>J. Am. Chem. Soc.</u> 118: 5938-5945 (1996)
22	Rosell, et al., "New Trifluoromethyl Ketones as Potent Inhibitors of Esterases: <sup>19</sup> F NMR Spectroscopy of Transition State Analog Complexes and Structure-Activity Relationships", <u>Biochem. Biophys. Res. Commun.</u> 226: 287-292 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Nancy Malsich  
Nancy Malsich

1/8/02

Date

---

Applicant:	Gilula, et al.	)	
		) Group:	1651
Serial No.:	09/894,790	)	
		)	
Filed:	June 28, 2001	) Examiner:	Unassigned
		)	
For:	FATTY-ACID AMIDE HYDROLASE	) Our Ref.:	TSRI 485.2 D1
		)	

---

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR §1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as

such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.


Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

---

1-8-02

Date



---

Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(858) 784-2937

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. TSRI 485.2 Div 1	SERIAL NO. 09/894,790
			APPLICANT Gilula, et al.	
			FILING DATE 6/28/2001	GROUP 1651
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)**

**EXAMINER** \_\_\_\_\_ **DATE CONSIDERED** \_\_\_\_\_



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Thomas E. Northrup  
Thomas E. Northrup, Reg. No. 33,268

3-16-00

Date

Applicant	:	Gilula, et al.	)	
			)	Group: 1651
Serial No.	:	08/743,168	)	
			)	
Filed	:	November 4, 1996	)	Examiner: I. Marx
			)	
For	:	FATTY-ACID AMIDE HYDROLASE	)	
			)	Our Ref. TSRI 485.2
			)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (c), and therefore is accompanied by a check in the amount of

\$240.00 as payment of the fee set forth in 37 CFR §1.17 (p).

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 3-16-00

By Thomas E. Northrup  
Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(858) 784-2937